Roche agreed to a multiyear collaboration and equity investment with Freenome to commercialize Freenome’s blood‑based cancer screening tests outside the U.S., a deal potentially worth more than $200 million including a $75 million equity stake. Roche will develop kit‑based, distributed versions of Freenome tests ex‑US while Freenome retains U.S. rights and centralized testing roles. The alliance couples Freenome’s early‑detection multiomic assays with Roche’s global diagnostics footprint and forthcoming sequencing‑by‑expansion (SBX) technology, plus access to Roche plasma cohorts to accelerate test validation. The deal signals industry momentum behind blood‑based early cancer detection and the pivot toward distributed, kit‑based screening. Sources: company statements and deal filings.